Skip to main content

Atossa Genetics Inks Distribution Deal with Fisher HealthCare for ForeCYTE

NEW YORK (GenomeWeb News) – Atossa Genetics today announced a distribution deal with Thermo Fisher Scientific's Fisher HealthCare for Atossa's ForeCYTE breast cancer test.

Fisher Healthcare will distribute the ForeCYTE Breast Health device, consisting of Atossa's US Food and Drug Administration-cleared Mammary Aspirate Specimen Cytology Test System, or MASCT, pump and ForeCYTE patient collection kits. ForeCYTE is a risk stratification test for breast cancer.

Financial and other terms of the deal were not disclosed.

Earlier this week, Atossa announced an agreement with preferred provider organization HealthSmart. Last month, the Seattle-based company signed a deal with Millennium Healthcare for distribution of ForeCYTE in the New York metro area and northern New Jersey.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.